Teclistamab for severe anti-MDA5 lung disease
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new medicine called teclistamab for people with a severe and rapidly progressing lung disease linked to anti-MDA5 antibodies. The goal is to see if the drug can stop the lung damage and improve breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have tested positive for anti-MDA5 antibodies (a marker of this lung condition).
- You have interstitial lung disease (ILD) confirmed by a special chest scan (HRCT).
- Your lung disease started less than 3 months ago.
- You have already tried high-dose steroids and two other immune-suppressing drugs for more than 7 days, but your lungs still got worse.
- You need extra oxygen or a breathing machine to keep your oxygen level above 95%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
This trial tests an experimental drug, teclistamab, for people with a type of amyloidosis (AL) that has not improved with standard treatments. It aims to see if teclistamab can help when other treatments have not worked.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
Hear when a new Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.